3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
70
Neoplasms
47
Carcinoma, Non-Small-Cell Lung
26
Colorectal Neoplasms
20
Neoplasm Metastasis
15
Multiple Myeloma
14
Thyroid Neoplasms
12
Glioma
12
Pancreatic Neoplasms
11
Hematologic Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Brain Neoplasms
8
Lung Neoplasms
7
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Neurofibromatosis 1
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Colonic Neoplasms
5
Breast Neoplasms
5
Astrocytoma
5
Thyroid Cancer, Papillary
4
Prostatic Neoplasms
4
Neurofibroma, Plexiform
4
Glioblastoma
4
Cholangiocarcinoma
4
Biliary Tract Neoplasms
4
Uveal Melanoma
3
Skin Neoplasms
3
Recurrence
3
Interventions
cobimetinib
2
trametinib
1
temsirolimus
1
dabrafenib
1
Vemurafenib
1
Valproic Acid
1
Specimen Handling
1
Sirolimus
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Biopsy
1
Bevacizumab
1
68Ga-pentixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Erdheim-Chester Disease
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled